A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

Phase 1 Completed 30 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple subcutaneous injections of SHR-2173 in patients with systemic lupus erythematosus (SLE).

Timeline

Start: 2024-11-24
Primary completion: 2025-11-10
Completion: 2025-11-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-2173	Unknown	—	Subcutaneous

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

Summary

Timeline

Drugs

Indications